Remission of disseminated cancer after systemic oncolytic virotherapy

Stephen J. Russell, Mark J. Federspiel, Kah Whye Peng, Caili Tong, David Dingli, William G. Morice, Val Lowe, Michael K. O'Connor, Robert A. Kyle, Nelson Leung, Francis K. Buadi, S. Vincent Rajkumar, Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri

Research output: Contribution to journalArticlepeer-review

181 Scopus citations


MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 1011 TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone-marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved with in the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.

Original languageEnglish (US)
Pages (from-to)926-933
Number of pages8
JournalMayo Clinic proceedings
Issue number7
StatePublished - Jul 2014

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Remission of disseminated cancer after systemic oncolytic virotherapy'. Together they form a unique fingerprint.

Cite this